the voting shares of The Safety Fund Corporation, Fitchburg, Massachusetts, and thereby indirectly acquire Safety Fund National Bank, Fitchburg, Massachusetts.

B. Federal Reserve Bank of Richmond (Lloyd W. Bostian, Jr., Senior Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

1. Macon Bancorp, Franklin, North Carolina; to become a bank holding company by acquiring 100 percent of the voting shares of Macon Savings Bank, SSB, Franklin, North Carolina.

Board of Governors of the Federal Reserve System, March 19, 1996.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 96–7053 Filed 3–22–96; 8:45 am]

BILLING CODE 6210–01–F

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.25 of Regulation Y (12 CFR 225.25) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act, including whether consummation of the proposal can ''reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices'' (12 U.S.C. 1843). Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 9, 1996.

A. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166:

1. Boatmen's Bancshares, Inc., St. Louis, Missouri; to engage *de novo* through its proposed subsidiary, BIS, Inc., Des Moines, Iowa, in insurance agency activities, which include the sales and servicing of personal lines (including but not limited to home, auto, health and general liability insurance), commercial lines of insurance, life insurance, health insurance and various bonding products, pursuant to § 225.23(b)(8)(iv) of the Board's Regulation Y. These activities will be conducted throughout Iowa, in each of the states surrounding Iowa, and in any other state in which insurance agency activities were conducted by the Marengo Agency, Des Moines, Iowa (a subsidiary of Boatmen's Bank Iowa, N.A., Des Moines, Iowa), on May 1, 1982.

Board of Governors of the Federal Reserve System, March 19, 1996.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 96–7052 Filed 3–22–96; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[INFO–96–13]

Proposed Data Collections Submitted for Public Comment and Recommendations

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call the CDC Reports Clearance Officer on (404) 639–7090.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques for other forms of information technology. Send comments to Wilma Johnson, CDC Reports Clearance Officer, 1600 Clifton Road, MS–D24, Atlanta, GA 30333. Written comments should be received within 60 days of this notice.

Proposed Projects

1. The HIV Epidemic in Small Cities and Rural Areas of the South—New—The HIV epidemic is increasingly spreading to small cities and rural areas of the South where little is known about the epidemic. Unlike other regions in the U.S., AIDS in the future is likely to be particularly severe in the South because STDs remain at epidemic levels in women and minorities in southern rural areas. Because funding is based on place of residence at diagnosis and because many patients with AIDS live in large metroplitan areas at diagnosis and then move to smaller cities and rural areas, resources may not be adequate for these patients after moving.

HIV-infected persons living in small cities and rural areas of the South will be interviewed to learn more about the circumstances of how they became infected and to determine what HIV-related health care services and prevention messages have been available to them before and after they became infected. Specific objectives include to: (1) Describe the demographics and modes of HIV transmission, (2) describe and compare high risk behaviors before and after being aware of their HIV infection, (3) determine in HIV-infected persons with a history of a sexually transmitted disease, the HIV/STD prevention services and messages that were offered when they were diagnosed with an STD at the visited health care sites, (4) determine the reasons for being HIV tested and the site and location of the HIV counseling and testing when the person first became HIV-positive and to describe the content of the counseling, (5) describe and compare HIV-related barriers to health care that HIV-infected persons have experienced in small MSAs and rural areas, (6) describe and compare characteristics of persons who acquired HIV infection in the area of current residence versus those who

acquired HIV before moving to their current residence, and (7) describe and compare the extent of and reasons for this migration in HIV-infected persons currently living in small cities and rural areas of the South. The total cost to respondents is estimated at $7,000.

Respondents	No. of respondents	No. of responses/respondent	Average burden/response (in hrs.)	Total burden (in hrs.)
HIV-infected adults receiving HIV care	700	.....	1	700
Total	.....	.....	.....	700

Dated: March 19, 1996.

Wilma G. Johnson,

Acting Associate Director for Policy Planning and Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–7137 Filed 3–22–96; 8:45 am]

BILLING CODE 4163–18–P

Food and Drug Administration

[Docket No. 96F–0092]

Asahi Denka Kogyo K.K.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Asahi Denka Kogyo K.K. has filed a petition proposing that the food additive regulations be amended to provide for the expanded safe use of phosphorous acid, cyclic neopentanetetrayl bis(2,6-di-*tert*-butyl-4-methylphenyl)ester as an antioxidant and/or stabilizer at a level not to exceed 0.05 percent by weight in olefin copolymers intended for use in contact with food.

DATES: Written comments on petitioner's environmental assessment by April 24, 1996.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Vir D. Anand, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3081.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 6B4498) has been filed by Asahi Denka Kogyo K.K., 2–13 Shirahata 5–Chome, Urawa City, Saitama 336, Japan. The petition proposes to amend the food additive regulations in § 178.2010 *Antioxidants and/or stabilizers in polymers* (21 CFR 178.2010) to expand the safe use of phosphorous acid, cyclic neopentanetetrayl bis(2,6-di-*tert*-butyl-4-methylphenyl)ester for use as an antioxidant and/or stabilizer at levels not to exceed 0.05 percent by weight of olefin polymers complying with 21 CFR 177.1520 intended for use in contact with food.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before April 24, 1996, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the Federal Register. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Dated: March 7, 1996.

Alan M. Rulis,

Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 96–7105 Filed 3–22–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 96D–0065]

''Medical Device Design Control Guidance'' and ''Do It By Design;'' Draft Guidance; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of two draft guidance documents entitled, ''Medical Device Design Control Guidance'' and ''Do It By Design.'' The ''Medical Device Design Control Guidance'' draft document is intended to provide a general understanding of design control theory, principles, and methods, and to update a previous guidance document on the subject of preproduction quality assurance. The ''Do It By Design'' draft guidance document is intended to provide a general understanding of the human factors theory as it relates to designing a medical device. Both draft guidance documents, once finalized, are intended to be basic educational tools for industry and FDA field investigators, and they will be used to aid implementation of the new ''quality system regulation,'' now in the final stages of development.

DATES: Written comments by April 30, 1996.

ADDRESSES: Submit written requests for single copies of the draft guidances to the Division of Small Manufacturers Assistance (DSMA), Center for Devices and Radiological Health (HFZ–220), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850. Send two self-addressed adhesive labels to assist the office in processing your request. Copies of a facsimile of the draft guidances are available from CDRH Facts on Demand (1–800–899–0381). Copies of the draft guidances may also be obtained from the Electronic Docket administered by DSMA and are available to anyone with a video terminal or personal computer (1–800–252–1366).

Submit written comments to the Dockets Management Branch (HFA–